Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer

被引：0
|
作者：
Boccardo, F. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Rubagotti, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Guglielmini, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Sismondi, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Farris, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Amadori, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Agostara, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Gambi, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Catalano, G. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Faedi, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
机构：
[1] Univ Genoa, Natl Inst Canc Res, Genoa, Italy
[2] Univ Mauriziano, Molinette Mauriziano Hosp, Turin, Italy
[3] Univ Sassari, I-07100 Sassari, Italy
[4] Tumor Inst Meldola, Forli, Italy
[5] M Ascoli Hosp, Palermo, Italy
[6] Infermi Hosp, Faenza, Italy
[7] Gen Hosp Pesaro, Pesaro, Italy
[8] Osped Gen Provinciale M Bufalini, Cesena, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11521
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Benefit of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide (CEX) versus 5-FU + epirubicin plus cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)
    Berton-Rigaud, D.
    Roche, H.
    Penault-Llorca, F.
    Tubiana-Mathieu, N.
    Ferrero, J.
    Coudert, B.
    Milano, G. A.
    Mousseau, M.
    Homokos, H.
    Fumoleau, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Adjuvant Therapy of Breast Cancer with Pirarubicin Versus Epirubicin in Combination with Cyclophosphamide and 5-fluorouracil
    Li, Jun-Jie
    Di, Gen-Hong
    Tang, Li-Chen
    Yu, Ke-Da
    Hu, Zhen
    Liu, Guang-Yu
    Lu, Jing-Song
    Wu, Jiong
    Han, Qi-Xia
    Shen, Zhen-Zhou
    Shao, Zhi-Ming
    BREAST JOURNAL, 2011, 17 (06): : 657 - 660
  • [33] Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer
    Kobayashi T.
    Koyama H.
    Oka T.
    Yasumura T.
    Kan N.
    Takatsuka Y.
    Noguchi M.
    Morimoto K.
    Suzuki T.
    Tobe T.
    Mori T.
    Breast Cancer, 1999, 6 (1) : 37 - 42
  • [34] Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
    Tokunaga, Shinya
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Kawajiri, Hidemi
    Tokumoto, Mao
    Nishimura, Shigehiko
    Nishimori, Takeo
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Yamagata, Shigehito
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2019, 39 (04) : 2053 - 2059
  • [35] A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer
    Robidoux, Andre
    Buzdar, Aman U.
    Quinaux, Emmanuel
    Jacobs, Samuel
    Rastogi, Priya
    Fourchotte, Virginie
    Younan, Rami J.
    Pajon, Eduardo R.
    Shalaby, Ibrahim A.
    Desai, Ajit M.
    Fehrenbacher, Louis
    Geyer, Charles E., Jr.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    CLINICAL BREAST CANCER, 2010, 10 (01) : 81 - 86
  • [36] Comparison of six cycles of epirubicin and paclitaxel (ET) versus four cycles of epirubicin and cyclophosphamide, followed by four cycles of paclitaxel (EC-T) as adjuvant therapy for operable breast cancer in women with positive axillary nodes
    Yuan, Peng
    Wang, Jiayu
    Ma, Fei
    Fan, Ying
    Luo, Yang
    Cai, Ruigang
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with breast cancer with 4 or more positive lymph nodes
    Boy, D.
    Murialdo, R.
    Angelini, I.
    Panariello, M.
    Tixi, L.
    Sacca, V.
    Piccardo, A.
    Ballestrero, A.
    BREAST, 2009, 18 : S55 - S55
  • [38] Paclitaxel and epirubicin versus 5-fluorouracil, epirubicin and cyclophosphamide in preoperative chemotherapy of stage III a and IIIB of chemotherapynaive breast cancer: Comparative analysis of response rate.
    Badulescu, A
    Badulescu, F
    Schenker, M
    Badea, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 71S - 71S
  • [39] High dose cyclophosphamide (C) and epirubicin (E) followed by cisplatin (P) and 5-fluorouracil (F) in patients with advanced epithelial ovarian adenocarcinoma (AEOC)
    Braud, AC
    Cottu, P
    Extra, JM
    Espie, M
    Cuvier, C
    Marty, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 551 - 551
  • [40] Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer
    Matsumoto, Akiko
    Jinno, Hiromitsu
    Naruse, Saki
    Isono, Yuka
    Maeda, Yuka
    Sato, Ayana
    Yamada, Miki
    Ikeda, Tatsuhiko
    Sasajima, Yuko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (12) : 1119 - 1124
12345